MAK Capital Tells Evotec to List US Unit Worth Over €1 billion

Activist fund MAK Capital, led by Michael A. Kaufman, has urged the leadership of German biotech firm Evotec SE to list its US unit and speed up its cost cutting program after the shares have lost about 85% over the past five years.